12:07 PM EDT, 09/16/2026 (MT Newswires) -- Novartis (NOVN.SW) halted the development of investigational drug VHB937 for the treatment of amyotrophic lateral sclerosis, or ALS, a fatal neurological disorder. In an emailed statement to MT Newswires on Wednesday, Novartis confirmed the discontinuation after the drug missed the primary and secondary endpoints of the phase 2 Astrals study. The Swiss pharmaceutical major's statement confirms the community update it shared with the European Organization for Professionals and People with ALS on Aug. 25. In that update, Novartis said it will present the study's detailed findings at the 37th International Symposium on ALS/MND in Amsterdam in December.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.